HAEM5:Extranodal NK/T-cell lymphoma - Revision history

Sumire.Kitahara: /* Primary Authors* */

2026-01-06T22:27:26Z

Primary Authors*

← Older revision		Revision as of 17:27, 6 January 2026
Line 4:		Line 4:
	==Primary Authors*==		==Primary Authors*==

	~~Teodora Popa, MD, Queen's University~~		<span class="blue-text">AUTHOR A</span>

			<span class="blue-text">AUTHOR B</span>

	~~Amanda Xu, MD, Queen's University~~
	==WHO Classification of Disease==		==WHO Classification of Disease==

Line 26:		Line 27:
	\|-		\|-
	\|Subtype(s)		\|Subtype(s)
	\|		\|Extranodal NK/T-cell lymphoma
	\|}		\|}
	==Related Terminology==		==Related Terminology==

	{\| class="wikitable"		{\| class="wikitable"
	\|+
	\|Acceptable		\|Acceptable
	\|Extranodal NK/T-cell lymphoma, nasal type; EBV-positive extranodal NK/T-cell lymphoma		\|Extranodal NK/T-cell lymphoma, nasal type; EBV-positive extranodal NK/T-cell lymphoma
Line 600:		Line 600:

	==Notes==		==Notes==

			<nowiki>*</nowiki>''Citation of this Page'': <span class="blue-text">AUTHOR A, AUTHOR B.</span> “Extranodal NK/T-cell lymphoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Extranodal_NK/T-cell_lymphoma</nowiki>.


	<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership\|''<u>Associate Editor</u>'']] or other CCGA representative. When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.		<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership\|''<u>Associate Editor</u>'']] or other CCGA representative. When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.

	Prior Author(s):		Prior Author(s): Teodora Popa, MD, Amanda Xu, MD


	~~<nowiki>*</nowiki>''Citation of this Page'': “Extranodal NK/T-cell lymphoma”. Compendium of Cancer Genome Aberrations (CCGA)~~, ~~Cancer Genomics Consortium (CGC)~~, ~~updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}~~, ~~<nowiki>https://ccga.io/index.php/HAEM5:Extranodal_NK/T-cell_lymphoma</nowiki>.~~
	[[Category:HAEM5]]		[[Category:HAEM5]]
	[[Category:DISEASE]]		[[Category:DISEASE]]
	[[Category:Diseases E]]		[[Category:Diseases E]]

Bailey.Glen at 17:15, 3 July 2025

2025-07-03T17:15:15Z

@@ Line 28: / Line 28: @@
+|
 |}
 ==Related Terminology==

Bailey.Glen at 21:34, 25 May 2025

2025-05-25T21:34:43Z

← Older revision		Revision as of 16:34, 25 May 2025
Line 75:		Line 75:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 149:		Line 149:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 203:		Line 203:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>''EGFR''		\|<span class="blue-text">EXAMPLE:</span>''EGFR''
Line 246:		Line 246:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene; Genetic Alteration!!~~'''~~Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)~~'''~~!!~~'''~~Prevalence (COSMIC / TCGA / Other)~~'''~~!!~~'''~~Concomitant Mutations~~'''~~!!~~'''~~Mutually Exclusive Mutations~~'''~~		!Gene; Genetic Alteration!!Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)!!Prevalence (COSMIC / TCGA / Other)!!Concomitant Mutations!!Mutually Exclusive Mutations
	!~~'''~~Diagnostic Significance (Yes, No or Unknown)~~'''~~		!Diagnostic Significance (Yes, No or Unknown)
	!Prognostic Significance (Yes, No or Unknown)		!Prognostic Significance (Yes, No or Unknown)
	!Therapeutic Significance (Yes, No or Unknown)		!Therapeutic Significance (Yes, No or Unknown)

Bailey.Glen at 20:11, 25 May 2025

2025-05-25T20:11:04Z

← Older revision		Revision as of 15:11, 25 May 2025
Line 43:		Line 43:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==
	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|Extranodal NK/T-cell lymphoma, nasal type; EBV-positive extranodal NK/T-cell lymphoma
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|Angiocentric lymphoma; lethal midline granuloma
	\|}		\|}

Bailey.Glen at 17:36, 24 March 2025

2025-03-24T17:36:42Z

← Older revision		Revision as of 12:36, 24 March 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Extranodal NK/T-cell lymphoma}}		{{DISPLAYTITLE:Extranodal NK/T-cell lymphoma}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

Line 8:		Line 7:

	Amanda Xu, MD, Queen's University		Amanda Xu, MD, Queen's University

	~~__TOC__~~

	==WHO Classification of Disease==		==WHO Classification of Disease==

Bailey.Glen: /* Gene Mutations (SNV/INDEL) */

2025-02-14T01:19:59Z

Gene Mutations (SNV/INDEL)

@@ Line 205: / Line 205: @@
 ==Gene Mutations (SNV/INDEL)==
 {| class="wikitable sortable"
 |-

Bailey.Glen: /* Characteristic Chromosomal or Other Global Mutational Patterns */

2025-02-14T01:19:17Z

Characteristic Chromosomal or Other Global Mutational Patterns

@@ Line 149: / Line 149: @@
 ==Characteristic Chromosomal or Other Global Mutational Patterns==
 {| class="wikitable sortable"
@@ Line 170: / Line 203: @@
 |N/A
 |}
 ==Gene Mutations (SNV/INDEL)==

Bailey.Glen: /* Individual Region Genomic Gain/Loss/LOH */

2025-02-14T01:18:46Z

Individual Region Genomic Gain/Loss/LOH

← Older revision		Revision as of 20:18, 13 February 2025
Line 77:		Line 77:

	==Individual Region Genomic Gain/Loss/LOH==		==Individual Region Genomic Gain/Loss/LOH==
			{\| class="wikitable sortable"
			\|-
			!Chr #!!'''Gain, Loss, Amp, LOH'''!!'''Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]'''!!'''Relevant Gene(s)'''
			!'''Diagnostic, Prognostic, and Therapeutic Significance - D, P, T'''
			!'''Established Clinical Significance Per Guidelines - Yes or No (Source)'''
			!'''Clinical Relevance Details/Other Notes'''
			\|-
			\|<span class="blue-text">EXAMPLE:</span>
			7
			\|<span class="blue-text">EXAMPLE:</span> Loss
			\|<span class="blue-text">EXAMPLE:</span>
			chr7
			\|<span class="blue-text">EXAMPLE:</span>
			Unknown
			\|<span class="blue-text">EXAMPLE:</span> D, P
			\|<span class="blue-text">EXAMPLE:</span> No
			\|<span class="blue-text">EXAMPLE:</span>
			Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference). Monosomy 7/7q deletion is associated with a poor prognosis in AML (add references).
			\|-
			\|<span class="blue-text">EXAMPLE:</span>
			8
			\|<span class="blue-text">EXAMPLE:</span> Gain
			\|<span class="blue-text">EXAMPLE:</span>
			chr8
			\|<span class="blue-text">EXAMPLE:</span>
			Unknown
			\|<span class="blue-text">EXAMPLE:</span> D, P
			\|
			\|<span class="blue-text">EXAMPLE:</span>
			Common recurrent secondary finding for t(8;21) (add references).
			\|-
			\|<span class="blue-text">EXAMPLE:</span>
			17
			\|<span class="blue-text">EXAMPLE:</span> Amp
			\|<span class="blue-text">EXAMPLE:</span>
			17q12; chr17:39,700,064-39,728,658 [hg38; 28.6 kb]
			\|<span class="blue-text">EXAMPLE:</span>
			''ERBB2''
			\|<span class="blue-text">EXAMPLE:</span> D, P, T
			\|
			\|<span class="blue-text">EXAMPLE:</span>
			Amplification of ''ERBB2'' is associated with HER2 overexpression in HER2 positive breast cancer (add references). Add criteria for how amplification is defined.
			\|-
			\|
			\|
			\|
			\|
			\|
			\|
			\|
			\|}

	{\| class="wikitable sortable"		{\| class="wikitable sortable"

Bailey.Glen: /* Gene Rearrangements */

2025-02-14T01:18:08Z

Gene Rearrangements

← Older revision		Revision as of 20:18, 13 February 2025
Line 58:		Line 58:

	==Gene Rearrangements==		==Gene Rearrangements==
	Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Details on clinical significance such as prognosis and other important information can be provided in the notes section. Please include references throughout the table. Do not delete the table.'')</span>
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-

Bailey.Glen: /* Gene Rearrangements */

2025-02-14T01:17:45Z

Gene Rearrangements

@@ Line 66: / Line 66: @@
 !Established Clinical Significance Per Guidelines - Yes or No (Source)
 !Clinical Relevance Details/Other Notes
 |-
+|